How to stop buying prescription medicines from the Arab world

How to stop buying prescription medicines from the Arab world

In recent years, an increasingly common practice among pharmacies has been to buy prescriptions from pharmacies located in the Arab countries of Jordan, Lebanon, and Syria.

The pharmacies are not required to be accredited by an international organization such as the Association of Pharmacists of Arab States (APASA), but most are, because they are seen as providing cheap, high-quality medications to the Arab population.

The practice is part of an increasingly widespread phenomenon of pharmacies in the Middle East, where prices for basic medicines have risen by as much as 90 percent since 2006.

As a result, more than a million Palestinians in the region have died from the effects of the drugs, according to the Palestinian Authority.

But the problem is not limited to the Middle Eastern region.

In 2016, the United States’ Consumer Product Safety Commission found that “the use of generic generic drugs in the United Kingdom and Ireland has increased more than sevenfold over the last five years.”

In the UK, the number of patients who took generic drugs jumped from 14,000 in 2010 to nearly 21,000 by 2018.

The U.S. has also seen a rise in the number and types of drugs available for purchase.

In 2018, generic medicines accounted for nearly half of all new generic medicines sold in the U.K., according to data from the UK drug regulator, which reported that sales in the country reached $3.6 billion in 2019.

A similar rise in sales of generic medicines was reported in the Netherlands, where the number rose from 4,500 in 2019 to nearly 23,000 last year.

In many cases, the rise in generic drug sales was not due to shortages, but to a rising number of people who are able to obtain them from the markets.

The rise in prescription drug prices has been driven by several factors, including the emergence of antibiotic resistance and the need to boost sales in an increasingly crowded marketplace.

In addition to the rise of the generic pharmaceutical market, the health of Palestinian patients has been suffering from the rise as well.

As the Palestinian economy has been crippled by the Israeli occupation and blockade, the Palestinian people have been unable to pay their bills.

The number of Palestinians without access to healthcare has increased by more than 80 percent over the past five years, according a report by the Palestinian Center for Policy and Survey Research (PPSR), which analyzed data from Palestinian hospitals in the occupied West Bank and Gaza Strip.

The Palestinian Center noted that “in 2018, almost 30 percent of the Palestinian population did not have access to any form of health care, compared to 6 percent in 2009 and 6 percent during the first half of the 1980s.”

The Palestinian Authority has also begun restricting access to essential medicines in some parts of the West Bank.

In recent months, a Palestinian man was arrested after he tried to sell a drug that he said was necessary to treat a kidney infection.

The man said that the drug was only available from a pharmaceutical company in Israel.

However, despite the rise, Palestinian patients still make up the vast majority of the population in the territories, with nearly half the population living under the poverty line.

According to Palestinian Health Ministry figures, there were 8.9 million Palestinians living in poverty in 2020.

Of those, 6.9 percent were in the Gaza Strip and the West Jerusalem area, and 4.6 percent in the West